ALA 3.45% 15.0¢ arovella therapeutics limited

7 June 2016 SUDA’s CEO, Mr Stephen Carter, commented: “We are...

  1. 8,592 Posts.
    lightbulb Created with Sketch. 1654
    7 June 2016

    SUDA’s CEO, Mr Stephen Carter, commented: “We are delighted to have a third manuscript published in the prestigious AAC journal. It confirms the importance of the clinical data and the high level of interest in ArTiMist™ amongst the scientific community in the field of malaria. The results from the two clinical efficacy studies clearly demonstrate that treatment with ArTiMist™ leads to superior parasite clearance and clinical recovery compared to intravenous quinine. We are working with our advisers as well as groups such as the Medicines for Malaria Venture to bring ArTiMist™ to the market at the earliest opportunity. This publication provides further endorsement of the product and supports our strategy for registration and partnering.”

    November 2015

    Commenting on SUDA’s business development progress, Mr Stephen Carter, Chief Executive Officer of SUDA said: “We are working hard to achieve our business development goals for FY2015/16. We have many sets of discussions that have reached an advanced stage, spanning several products and territories. Hence, we remain confident in our strategy and operational direction. I look forward to announcing a series of out-licensing deals in due course. Furthermore, I am delighted by the reception we received from philanthropic funds that are interested in supporting an expansion of the use of ArTiMist™ to treating paediatric malaria in the pre-referral setting.

    2015 Highlights|
    Adding value to ArTiMist™ § Expanding the use of ArTiMist™ as an early interven=onal ‘pre-referral’ therapy - Clinical Advisory Board has finalised the clinical protocol - Ongoing support from the Medicines for Malaria Venture - Global philanthropic funds have indicated interest in funding the trial § Pursuing adop=on by WHO in Treatment Guidelines for severe paediatric malaria - Ongoing dialogue with WHO’s Global Malarial Programme - Preparing to submit for stringent regulatory review by the TGA in Australia - Three peer-reviewed papers published in pres=gious US medical journal
 
watchlist Created with Sketch. Add ALA (ASX) to my watchlist
(20min delay)
Last
15.0¢
Change
0.005(3.45%)
Mkt cap ! $138.7M
Open High Low Value Volume
14.5¢ 15.0¢ 14.0¢ $301.1K 2.087M

Buyers (Bids)

No. Vol. Price($)
3 79105 14.0¢
 

Sellers (Offers)

Price($) Vol. No.
15.0¢ 357820 9
View Market Depth
Last trade - 16.10pm 29/03/2024 (20 minute delay) ?
Last
14.5¢
  Change
0.005 ( 2.84 %)
Open High Low Volume
14.5¢ 15.0¢ 14.0¢ 441083
Last updated 15.34pm 29/03/2024 ?
ALA (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.